Hepatitis C Virus

Company initiates phase Ib study of GI-5005 for chronic hepatitis C infection

Published in Virus Weekly, August 23rd, 2005

GlobeImmune, Inc., a biopharmaceutical company that discovers, develops, and manufactures immunotherapeutic products known as Tarmogens to treat cancer and infectious disease, announced that it has initiated a phase Ib study of GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection (HCV).

This study is being conducted under an investigational new drug application that was filed with the U.S. Food and Drug Administration in March 2005.

The phase Ib study is a double-blind, placebo-controlled, dose-escalation, multicenter trial evaluating the safety, immunogenicity, and efficacy of GI-5005, a Tarmogen expressing a NS3-Core fusion...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Virus Weekly

Source: Virus Weekly (2005-08-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry